Stocksigma LogoStocksigma Logo

Vista Pharmaceuticals: Zero Revenue, Growing Losses, and Going Concern Risk in Q1FY27

Vista Pharmaceuticals reported zero revenue from operations for Q1FY27 ended 30 Jun'26, down from ₹151.88 lakhs YoY

Vista Pharmaceuticals: Zero Revenue, Growing Losses, and Going Concern Risk in Q1FY27

Vista Pharmaceuticals Ltd · Outcome · 14 Aug 2026, 9:06 pm

Vista Pharmaceuticals: Zero Revenue, Growing Losses, and Going Concern Risk in Q1FY27 Vista Pharmaceuticals reported zero revenue from operations for Q1FY27 ended 30 Jun'26, down from ₹151.88 lakhs YoY. The net loss narrowed slightly to ₹98.59 lakhs from ₹129.04 lakhs YoY, while the loss before tax was ₹132.71 lakhs. Significant financial stress is evident, with credit facilities classified as NPAs, negative working capital, and current liabilities exceeding current assets by ₹183.32 lakhs. These factors raise material uncertainty about its ability to continue as a going concern, despite management preparing results on that basis.

Original exchange filing (PDF)

More announcements from Vista Pharmaceuticals Ltd

All Vista Pharmaceuticals Ltd announcements